Isoniazid acetylation metabolic ratio during maturation in children

Clinical Pharmacology and Therapeutics

Volumn 62, Issue 4, 1997, Pages 377-383

  Pariente Khayat, Ann ^b   Rey, Elisabeth ^b   Gendrel, Dominique ^b   Vauzelle Kervroëdan, Françoise ^b   Crémier, Odile ^b   D'Athis, Philippe ^b   Badoual, Jean ^b   Olive, Georges ^b   Pons, Gérard ^a  

^a HÔPITAL SAINT VINCENT DE PAUL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLISONIAZID; ISONIAZID;

ACETYLATOR PHENOTYPE; ARTICLE; CHILD; CLINICAL TRIAL; DRUG ACETYLATION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TUBERCULOSIS;

ACETYLATION; ADOLESCENT; AGING; ANTITUBERCULAR AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; INFANT, NEWBORN; ISONIAZID; PHENOTYPE; RETROSPECTIVE STUDIES;

EID: 0030707566     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(97)90115-6     Document Type: Article

References (18)

1. Grant DM, Blum M, Beer M, Meyer UA. Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. Mol Pharmacol 1991;39:184-91.
2. Price Evans DA. N-Acetyltransferase. Pharmacol Ther 1989;42:157-234.
3. Ellard GA, Gammon PT. Pharmacokinetics of isoniazid metabolism in man. J Pharmacokinet Biopharm 1975;4:83-113.
4. Weber WW, Hein DW. Clinical pharmacokinetics of isoniazid. Clin Pharmacokinet 1979;4:401-22.
5. Price Evans DA, Manley KA, McKusick VA. Genetic control of isoniazid metabolism in man. Br Med J 1960;2:485-91.
6. Kalow W. Ethnic differences in drug metabolism. Clin Pharmacokinet 1982;7:373-400.
7. Miscoria G, Leneveu A, Walle C, Roux A. Application d'une méthode de dosage de l'isoniazide et de l'acetylisoniazide par chromatographie liquide haute performance à la détermination du phénotype d'acétylation. Ann Biol Clin (Paris) 1988;46:734-40.
8. Pons G, Key E, Carrier O, Richard MO, Moran C, Badoual J, et al. Maturation of AFMU excretion in infants. Fundam Clin Pharmacol 1989;3:589-95.
9. Pariente-Khayat A, Pons G, Rey E, Richard MO, d'Athis P, Moran C, et al. Caffeine acetylator phenotyping during maturation in infants. Pediatr Res 1991; 29:492-5.
10. Rey E, Pons G, Crémier O, Vauzelle-Kervroëdan F, Pariente-Khayat A, d'Athis P, et al. Isoniazid dose adjustment in a pediatric population. Ther Drug Monit [in press].
11. Gex-Fabry M, Balant LP. Considerations on data analysis using computer methods and currently available software for personal computers. In: Welling PG, Balant LP, editors. Handbook of experimental pharmacology: pharmacokinetics of drugs. Berlin: Springer-Verlag; 1994. p. 110.
12. Endrenyi L, Patel M. A new sensitive method for detecting deviations from the normal distribution of drug responses: the NTV plot. Br J Clin Pharmacol 1991;32:159-66.
13. Hutchings A, Routledge A. A simple method for determining acetylator phenotype using isoniazid. Br J Clin Pharmacol 1986;22:343-5.
14. Mashimo M, Suzuki T, Abe M, Deguchi T. Molecular genotyping of N-acetylation polymorphism to predict phenotype. Hum Genet 1992;90:139-43.
15. Chapron DJ, Kramer PA, Mercik SA. Kinetic discrimination of three sulfamethazine acetylation phenotypes. Clin Pharmacol Ther 1980;27:104-13.
16. Ellard GA, Gammon PT. Acetylator phenotyping of tuberculosis patients using matrix isoniazid or sulphadimidine and its prognostic significance for treatment with several intermittent isoniazid-containing regimens. Br J Clin Pharmacol 1977;4:5-14.
17. Israili ZH, Rogers CM, El-Attar H. Pharmacokinetics of antituberculosis drugs in patients. J Clin Pharmacol 1987;27:78-83.
18. Bouveret JP, Hanoteau J, Gerbeaux J, Houin G, Tillement JP. Variations de l'indice d'inactivation de l'isoniazide au cours des traitements antituberculeux chez l'enfant. Arch Fr Pediatr 1983;40:615-9.